# Arsenal Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arsenal-biosciences

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.arsenalbio.com/
- Total disclosed funding: $631M
- Latest round: Series C (Jul 9, 2024)
- Investors on record: 20

## About

Founded in 2019 and headquartered in San Francisco, US, Arsenal Biosciences, Inc. develops cell therapies for cancer treatment. The company was established by Ken Drazan (CEO), Kole Roybal, Nicholas Haining, John Wherry, Alexander Marson, and Brad Bernstein. In July 2024, Arsenal Biosciences, Inc. raised USD 325 million in series C funding co-led by ARCH Venture Partners, Luma Group, Milky Way Investments Group, Nventures, Regeneron Ventures, Rock Springs Capital, T Rowe Price, Bristol-Myers Squibb Company, Byers Capital, Kleiner Perkins, Hitachi Ventures, Parker Institute for Cancer Immunotherapy, SB Investment Advisers, and Westlake Village BioPartners. The series C funding values Arsenal Biosciences, Inc. at USD 1.65 billion post-money.

Arsenal Biosciences, Inc. specializes in developing programmable cell therapies aimed at tackling solid tumors in cancer patients. The company's primary innovation lies in its proprietary technology that enables the engineering of T cells to target and destroy cancer cells. ArsenalBio assembles a diverse team of experts across multiple scientific disciplines to create therapies that enhance patient outcomes, focusing on the complex nature of solid tumors. Their products are primarily aimed at clinical institutions and healthcare providers in North America and Europe, catering to oncologists and healthcare systems that require advanced treatment options for cancer patients.

Arsenal Biosciences operates on a revenue model driven by partnerships and collaborations with pharmaceutical companies and research institutions. Revenue is generated through transactional agreements where ArsenalBio provides its cell therapy technologies to partners, resulting in payments and potential royalties based on product performance and sales, particularly for flagship therapies developed under the AB-4000 series.

The company plans to innovate tools and processes for developing new candidate cell therapies. ArsenalBio is also targeting expansion into new geographic markets, furthering its reach to enhance distribution of its innovative therapies.

## Funding rounds

- Series C, Jul 9, 2024, $325M — ARCH Venture Partners, Kleiner Perkins, T Rowe Price, Bristol-Myers Squibb Company, Rock Springs Capital, SB Investment Advisers, Nventures, Parker Institute for Cancer Immunotherapy, Westlake Village BioPartners, Hitachi Ventures, Byers Capital, Luma Group, Regeneron Ventures
- Series B, Feb 10, 2022, $221M — Kleiner Perkins, Bristol-Myers Squibb Company, UC San Francisco Foundation, Waycross Ventures, Euclidean Capital, SB Investment Advisers, Sixth Street, Parker Institute for Cancer Immunotherapy, Westlake Village BioPartners, Hitachi Ventures, Green Sands Equity, Byers Capital, Emerson Collective
- Series A, Oct 17, 2019, $85M — Kleiner Perkins, UC San Francisco Foundation, Euclidean Capital, Parker Institute for Cancer Immunotherapy, Westlake Village BioPartners, Osage Venture Partners

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A, Series B, Series C
- UC San Francisco Foundation — Series A, Series B
- Euclidean Capital — Series A, Series B
- Parker Institute for Cancer Immunotherapy — Series A, Series B, Series C
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series A, Series B, Series C
- Osage Venture Partners (https://capitalatlas.ai/funds/osage-venture-partners) — Series A
- Bristol-Myers Squibb Company — Series B, Series C
- Waycross Ventures — Series B
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series B, Series C
- Sixth Street (https://capitalatlas.ai/funds/sixth-street) — Series B
- Hitachi Ventures (https://capitalatlas.ai/funds/hitachi-ventures) — Series B, Series C
- Green Sands Equity (https://capitalatlas.ai/funds/green-sands-equity) — Series B
- Byers Capital (https://capitalatlas.ai/funds/byers-capital) — Series B, Series C
- Emerson Collective — Series B
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- Rock Springs Capital — Series C
- Nventures — Series C
- Luma Group (https://capitalatlas.ai/funds/luma-group) — Series C
- Regeneron Ventures (https://capitalatlas.ai/funds/regeneron-ventures) — Series C